Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/ar3400.

Title:
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells | Arthritis Research & Therapy
Description:
Introduction The aim was to determine the effect of the Bruton tyrosine kinase (Btk)-selective inhibitor PCI-32765, currently in Phase I/II studies in lymphoma trials, in arthritis and immune-complex (IC) based animal models and describe the underlying cellular mechanisms. Methods PCI-32765 was administered in a series of murine IC disease models including collagen-induced arthritis (CIA), collagen antibody-induced arthritis (CAIA), reversed passive anaphylactic reaction (RPA), and passive cutaneous anaphylaxis (PCA). Clinical and pathologic features characteristic of each model were examined following treatment. PCI-32765 was then examined in assays using immune cells relevant to the pathogenesis of arthritis, and where Btk is thought to play a functional role. These included proliferation and calcium mobilization in B cells, cytokine and chemokine production in monocytes/macrophages, degranulation of mast cells and its subsequent cytokine/chemokine production. Results PCI-32765 dose-dependently and potently reversed arthritic inflammation in a therapeutic CIA model with an ED50 of 2.6 mg/kg/day. PCI-32765 also prevented clinical arthritis in CAIA models. In both models, infiltration of monocytes and macrophages into the synovium was completely inhibited and importantly, the bone and cartilage integrity of the joints were preserved. PCI-32765 reduced inflammation in the Arthus and PCA assays. In vitro, PCI-32765 inhibited BCR-activated primary B cell proliferation (IC50 = 8 nM). Following FcγR stimulation, PCI-32765 inhibited TNFα, IL-1β and IL-6 production in primary monocytes (IC50 = 2.6, 0.5, 3.9 nM, respectively). Following FcεRI stimulation of cultured human mast cells, PCI-32765 inhibited release of histamine, PGD2, TNF-α, IL-8 and MCP-1. Conclusions PCI-32765 is efficacious in CIA, and in IC models that do not depend upon autoantibody production from B cells. Thus PCI-32765 targets not only B lymphocytes but also monocytes, macrophages and mast cells, which are important Btk-expressing effector cells in arthritis.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

pci, cells, human, pubmed, article, arthritis, btk, mice, mast, google, scholar, cell, macrophages, cas, monocytes, figure, bone, inhibition, inflammation, release, activation, cia, inhibited, kinase, tyrosine, primary, tnfα, treatment, models, mgkg, treated, disease, cartilage, fcγr, signaling, shown, hours, minutes, vehicle, clinical, immune, stimulation, usa, igg, blue, caia, mcp, file, immunol, inhibitor,

Topics {✒️}

relapsed/refractory b-cell malignancies c-jun n-terminus kinase anti-cd3/anti-cd28 stimulations collagen antibody-induced arthritis 5 μg/ml anti-cd3/cd28 b-cell antigen receptor antibody-dependent antitumor cytotoxicity passive cutaneous anaphylactic article download pdf b-cell receptor activation human x-linked agammaglobulinemia pci-32765 dose-dependently inhibited animal micro-ct scanner autoimmune-mediated hemolytic anemia extracellular signal-regulated kinase fcgamma receptor-induced signaling rankl-induced osteoclastic differentiation goat anti-human igm reversed passive anaphylactic osteo-arthritic human hips pci-32765 dose-dependently reduced human ic-mediated diseases anti-cd20-percp-cy5 mucosal-type mast cells incubating plate-bound cfb inhibits fcγr-induced release immune-complex mediated fcγr collagen-induced arthritis immune-complex mediated activation x-linked agammaglobulinemia patients goat anti-human igg anti-citrullinated protein antibody full size image pci-32765 inhibits anti-dnp immune-mediated inflammatory disease passive cutaneous anaphylaxis mitogen-activated protein kinase cr3-mediated monocyte phagocytosis hind/fore limbs excised dose-dependently inhibited b-cell lymphoma bcr-mediated cell activation human monocyte-derived macrophages mann-whitney u-test idiopathic thrombocytopenic purpura x-linked agammaglobulinemia b-cell malignancy collagan-induced arthritis inhibits cytokine/chemokine release ic-mediated vasculitis

Questions {❓}

  • Lindstrom TM, Robinson WH: A multitude of kinases - which are the best targets in treating rheumatoid arthritis?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
         description:The aim was to determine the effect of the Bruton tyrosine kinase (Btk)-selective inhibitor PCI-32765, currently in Phase I/II studies in lymphoma trials, in arthritis and immune-complex (IC) based animal models and describe the underlying cellular mechanisms. PCI-32765 was administered in a series of murine IC disease models including collagen-induced arthritis (CIA), collagen antibody-induced arthritis (CAIA), reversed passive anaphylactic reaction (RPA), and passive cutaneous anaphylaxis (PCA). Clinical and pathologic features characteristic of each model were examined following treatment. PCI-32765 was then examined in assays using immune cells relevant to the pathogenesis of arthritis, and where Btk is thought to play a functional role. These included proliferation and calcium mobilization in B cells, cytokine and chemokine production in monocytes/macrophages, degranulation of mast cells and its subsequent cytokine/chemokine production. PCI-32765 dose-dependently and potently reversed arthritic inflammation in a therapeutic CIA model with an ED50 of 2.6 mg/kg/day. PCI-32765 also prevented clinical arthritis in CAIA models. In both models, infiltration of monocytes and macrophages into the synovium was completely inhibited and importantly, the bone and cartilage integrity of the joints were preserved. PCI-32765 reduced inflammation in the Arthus and PCA assays. In vitro, PCI-32765 inhibited BCR-activated primary B cell proliferation (IC50 = 8 nM). Following FcγR stimulation, PCI-32765 inhibited TNFα, IL-1β and IL-6 production in primary monocytes (IC50 = 2.6, 0.5, 3.9 nM, respectively). Following FcεRI stimulation of cultured human mast cells, PCI-32765 inhibited release of histamine, PGD2, TNF-α, IL-8 and MCP-1. PCI-32765 is efficacious in CIA, and in IC models that do not depend upon autoantibody production from B cells. Thus PCI-32765 targets not only B lymphocytes but also monocytes, macrophages and mast cells, which are important Btk-expressing effector cells in arthritis.
         datePublished:2011-07-13T00:00:00Z
         dateModified:2011-07-13T00:00:00Z
         pageStart:1
         pageEnd:15
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/ar3400
         keywords:
            Mast Cell
            Evans Blue
            Human Mast Cell
            Passive Cutaneous Anaphylactic
            Bruton Tyrosine Kinase
            Rheumatology
            Orthopedics
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig5_HTML.jpg
         isPartOf:
            name:Arthritis Research & Therapy
            issn:
               1478-6354
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Betty Y Chang
               affiliation:
                     name:Pharmacyclics, Inc., Research Department
                     address:
                        name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Min Mei Huang
               affiliation:
                     name:Pharmacyclics, Inc., Research Department
                     address:
                        name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michelle Francesco
               affiliation:
                     name:Pharmacyclics, Inc., Research Department
                     address:
                        name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jun Chen
               affiliation:
                     name:Pharmacyclics, Inc., Research Department
                     address:
                        name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jeremy Sokolove
               affiliation:
                     name:Stanford University School of Medicine
                     address:
                        name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
                        type:PostalAddress
                     type:Organization
                     name:VA Palo Alto Health Care System
                     address:
                        name:VA Palo Alto Health Care System, Palo Alto, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Padmaja Magadala
               affiliation:
                     name:Pharmacyclics, Inc., Research Department
                     address:
                        name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:William H Robinson
               affiliation:
                     name:Stanford University School of Medicine
                     address:
                        name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
                        type:PostalAddress
                     type:Organization
                     name:VA Palo Alto Health Care System
                     address:
                        name:VA Palo Alto Health Care System, Palo Alto, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joseph J Buggy
               affiliation:
                     name:Pharmacyclics, Inc., Research Department
                     address:
                        name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
      description:The aim was to determine the effect of the Bruton tyrosine kinase (Btk)-selective inhibitor PCI-32765, currently in Phase I/II studies in lymphoma trials, in arthritis and immune-complex (IC) based animal models and describe the underlying cellular mechanisms. PCI-32765 was administered in a series of murine IC disease models including collagen-induced arthritis (CIA), collagen antibody-induced arthritis (CAIA), reversed passive anaphylactic reaction (RPA), and passive cutaneous anaphylaxis (PCA). Clinical and pathologic features characteristic of each model were examined following treatment. PCI-32765 was then examined in assays using immune cells relevant to the pathogenesis of arthritis, and where Btk is thought to play a functional role. These included proliferation and calcium mobilization in B cells, cytokine and chemokine production in monocytes/macrophages, degranulation of mast cells and its subsequent cytokine/chemokine production. PCI-32765 dose-dependently and potently reversed arthritic inflammation in a therapeutic CIA model with an ED50 of 2.6 mg/kg/day. PCI-32765 also prevented clinical arthritis in CAIA models. In both models, infiltration of monocytes and macrophages into the synovium was completely inhibited and importantly, the bone and cartilage integrity of the joints were preserved. PCI-32765 reduced inflammation in the Arthus and PCA assays. In vitro, PCI-32765 inhibited BCR-activated primary B cell proliferation (IC50 = 8 nM). Following FcγR stimulation, PCI-32765 inhibited TNFα, IL-1β and IL-6 production in primary monocytes (IC50 = 2.6, 0.5, 3.9 nM, respectively). Following FcεRI stimulation of cultured human mast cells, PCI-32765 inhibited release of histamine, PGD2, TNF-α, IL-8 and MCP-1. PCI-32765 is efficacious in CIA, and in IC models that do not depend upon autoantibody production from B cells. Thus PCI-32765 targets not only B lymphocytes but also monocytes, macrophages and mast cells, which are important Btk-expressing effector cells in arthritis.
      datePublished:2011-07-13T00:00:00Z
      dateModified:2011-07-13T00:00:00Z
      pageStart:1
      pageEnd:15
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/ar3400
      keywords:
         Mast Cell
         Evans Blue
         Human Mast Cell
         Passive Cutaneous Anaphylactic
         Bruton Tyrosine Kinase
         Rheumatology
         Orthopedics
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3400/MediaObjects/13075_2011_Article_3163_Fig5_HTML.jpg
      isPartOf:
         name:Arthritis Research & Therapy
         issn:
            1478-6354
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Betty Y Chang
            affiliation:
                  name:Pharmacyclics, Inc., Research Department
                  address:
                     name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Min Mei Huang
            affiliation:
                  name:Pharmacyclics, Inc., Research Department
                  address:
                     name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michelle Francesco
            affiliation:
                  name:Pharmacyclics, Inc., Research Department
                  address:
                     name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jun Chen
            affiliation:
                  name:Pharmacyclics, Inc., Research Department
                  address:
                     name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jeremy Sokolove
            affiliation:
                  name:Stanford University School of Medicine
                  address:
                     name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
                     type:PostalAddress
                  type:Organization
                  name:VA Palo Alto Health Care System
                  address:
                     name:VA Palo Alto Health Care System, Palo Alto, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Padmaja Magadala
            affiliation:
                  name:Pharmacyclics, Inc., Research Department
                  address:
                     name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:William H Robinson
            affiliation:
                  name:Stanford University School of Medicine
                  address:
                     name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
                     type:PostalAddress
                  type:Organization
                  name:VA Palo Alto Health Care System
                  address:
                     name:VA Palo Alto Health Care System, Palo Alto, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joseph J Buggy
            affiliation:
                  name:Pharmacyclics, Inc., Research Department
                  address:
                     name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Arthritis Research & Therapy
      issn:
         1478-6354
      volumeNumber:13
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Pharmacyclics, Inc., Research Department
      address:
         name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
         type:PostalAddress
      name:Pharmacyclics, Inc., Research Department
      address:
         name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
         type:PostalAddress
      name:Pharmacyclics, Inc., Research Department
      address:
         name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
         type:PostalAddress
      name:Pharmacyclics, Inc., Research Department
      address:
         name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
         type:PostalAddress
      name:Stanford University School of Medicine
      address:
         name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
         type:PostalAddress
      name:VA Palo Alto Health Care System
      address:
         name:VA Palo Alto Health Care System, Palo Alto, USA
         type:PostalAddress
      name:Pharmacyclics, Inc., Research Department
      address:
         name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
         type:PostalAddress
      name:Stanford University School of Medicine
      address:
         name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
         type:PostalAddress
      name:VA Palo Alto Health Care System
      address:
         name:VA Palo Alto Health Care System, Palo Alto, USA
         type:PostalAddress
      name:Pharmacyclics, Inc., Research Department
      address:
         name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Betty Y Chang
      affiliation:
            name:Pharmacyclics, Inc., Research Department
            address:
               name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Min Mei Huang
      affiliation:
            name:Pharmacyclics, Inc., Research Department
            address:
               name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
               type:PostalAddress
            type:Organization
      name:Michelle Francesco
      affiliation:
            name:Pharmacyclics, Inc., Research Department
            address:
               name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
               type:PostalAddress
            type:Organization
      name:Jun Chen
      affiliation:
            name:Pharmacyclics, Inc., Research Department
            address:
               name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
               type:PostalAddress
            type:Organization
      name:Jeremy Sokolove
      affiliation:
            name:Stanford University School of Medicine
            address:
               name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
               type:PostalAddress
            type:Organization
            name:VA Palo Alto Health Care System
            address:
               name:VA Palo Alto Health Care System, Palo Alto, USA
               type:PostalAddress
            type:Organization
      name:Padmaja Magadala
      affiliation:
            name:Pharmacyclics, Inc., Research Department
            address:
               name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
               type:PostalAddress
            type:Organization
      name:William H Robinson
      affiliation:
            name:Stanford University School of Medicine
            address:
               name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
               type:PostalAddress
            type:Organization
            name:VA Palo Alto Health Care System
            address:
               name:VA Palo Alto Health Care System, Palo Alto, USA
               type:PostalAddress
            type:Organization
      name:Joseph J Buggy
      affiliation:
            name:Pharmacyclics, Inc., Research Department
            address:
               name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
      name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
      name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
      name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
      name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
      name:VA Palo Alto Health Care System, Palo Alto, USA
      name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA
      name:Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford
      name:VA Palo Alto Health Care System, Palo Alto, USA
      name:Pharmacyclics, Inc., Research Department, Sunnyvale, USA

External Links {🔗}(194)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.45s.